Vaishnav J, Yanek LR, Chasler JE, et al. - By analyzing participants in the Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine trial, researchers assessed the impact of dopamine (DA) on heart failure with preserved ejection fraction (HFpEF) patients with right ventricular dysfunction (RVD)(HFpEF-RVD), given that treatment with low-dose DA has not demonstrated benefit decompensated HF. Findings revealed the presence of RVD in 29% (24 of 82) of the cohort. Lower BMI, higher Cr, and higher NT-proBNP were detected in HFpEF-RVD patients vs HFpEF-no RVD. An inverse link of BMI with HFpEF-RVD was revealed following adjustment for age, gender, and race. Overall, a sicker subgroup of HFpEF patients was reflected by HFpEF-RVD. Findings revealed shorter length of stay in HFpEF-RVD in correlation with low-dose DA in hospitalized HFpEF.